Urokinase Plasminogen Activator Regulates Pulmonary Arterial Contractility and Vascular Permeability in Mice
- 1 November 2011
- journal article
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 45 (5) , 1015-1021
Abstract
The concentration of urokinase plasminogen activator (uPA) is elevated in pathological settings such as acute lung injury, where pulmonary arterial contractility and permeability are disrupted. uPA limits the accretion of fibrin after injury. Here we investigated whether uPA also regulates pulmonary arterial contractility and permeability. Contractility was measured using isolated pulmonary arterial rings. Pulmonary blood flow was measured in vivo by Doppler and pulmonary vascular permeability, according to the extravasation of Evans blue. Our data show that uPA regulates the in vitro pulmonary arterial contractility induced by phenylephrine in a dose-dependent manner through two receptor-dependent pathways, and regulates vascular contractility and permeability in vivo. Physiological concentrations of uPA (≤1 nM) stimulate the contractility of pulmonary arterial rings induced by phenylephrine through the low-density lipoprotein receptor–related protein receptor. The procontractile effect of uPA is independent of its catalytic activity. At pathophysiological concentrations, uPA (20 nM) inhibits contractility and increases vascular permeability. The inhibition of vascular contractility and increase of vascular permeability is mediated through a two-step process that involves docking to N-methyl-d-aspartate receptor–1 (NMDA-R1) on pulmonary vascular smooth muscle cells, and requires catalytic activity. Peptides that specifically inhibit the docking of uPA to NMDA-R, or the uPA variant with a mutated receptor docking site, abolished both the effects of uPA on vascular contractility and permeability, without affecting its catalytic activity. These data show that uPA, at concentrations found under pathological conditions, reduces pulmonary arterial contractility and increases permeability though the activation of NMDA-R1. The selective inhibition of NMDAR-1 activation by uPA can be accomplished without a loss of fibrinolytic activity.Keywords
This publication has 43 references indexed in Scilit:
- Regulation of Airway Contractility by Plasminogen Activators through N-Methyl-D-Aspartate Receptor–1American Journal of Respiratory Cell and Molecular Biology, 2010
- Inhalation of urokinase-type plasminogen activator reduces airway remodeling in a murine asthma modelAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2009
- Constriction of carotid arteries by urokinase-type plasminogen activator requires catalytic activity and is independent of NH2-terminal domainsThrombosis and Haemostasis, 2009
- uPA impairs cerebrovasodilation after hypoxia/ischemia through LRP and ERK MAPKBrain Research, 2008
- Toward Safer Thrombolytic Agents in Stroke: Molecular Requirements for NMDA Receptor-Mediated NeurotoxicityJournal of Cerebral Blood Flow & Metabolism, 2008
- Plasminogen Activators Contribute to Impairment of Hypercapnic and Hypotensive Cerebrovasodilation After Cerebral Hypoxia/Ischemia in the Newborn PigStroke, 2005
- The kringle domain of urokinase-type plasminogen activator potentiates LPS-induced neutrophil activation through interaction with αVβ3 integrinsJournal of Leukocyte Biology, 2005
- Plasminogen activators contribute to age-dependent impairment of NMDA cerebrovasodilation after brain injuryDevelopmental Brain Research, 2005
- Plasminogen activator inhibitor-1 in acute hyperoxic mouse lung injury.Journal of Clinical Investigation, 1996
- Depressed Bronchoalveolar Urokinase Activity in Patients with Adult Respiratory Distress SyndromeNew England Journal of Medicine, 1990